A Randomised, Parallel-Arm, Open-Label Trial Comparing Degarelix With Goserelin Plus Anti-Androgen Flare Protection (Bicalutamide), in Terms of Volume Reduction of the Prostate in Patients With Prostate Cancer Being Candidates for Medical Castration.

Next Previous
Trial Profile

A Randomised, Parallel-Arm, Open-Label Trial Comparing Degarelix With Goserelin Plus Anti-Androgen Flare Protection (Bicalutamide), in Terms of Volume Reduction of the Prostate in Patients With Prostate Cancer Being Candidates for Medical Castration.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Apr 2014

At a glance

  • Drugs Degarelix (Primary) ; Bicalutamide; Goserelin
  • Indications Prostate cancer
  • Focus Pharmacodynamics; Registrational

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 15 Apr 2014 Results from a pooled analysis presented at the 29th Congress of the European Association of Urology.
    • 13 Apr 2012 Results published in the BJU International.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top